Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Profit After Tax: 2016-2025

Historic Profit After Tax for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $31.5 million.

  • Collegium Pharmaceutical's Profit After Tax rose 237.51% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 34.03%. This contributed to the annual value of $69.2 million for FY2024, which is 43.68% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Profit After Tax stood at $31.5 million for Q3 2025, which was up 162.93% from $12.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Profit After Tax high stood at $72.8 million for Q2 2021, and its period low was -$25.0 million during Q4 2021.
  • Its 3-year average for Profit After Tax is $14.8 million, with a median of $13.0 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first slumped by 459.79% in 2021, then spiked by 4,415.10% in 2023.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Profit After Tax stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then plummeted by 60.75% to $12.5 million in 2024, then surged by 237.51% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $12.0 million for Q2 2025, and $2.4 million during Q1 2025.